Chemotherapy before surgery for advanced ovarian cancer with high PARK2
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial compares two chemotherapy drugs (paclitaxel alone vs. paclitaxel plus carboplatin) given before surgery for advanced ovarian cancer. It is specifically for people whose tumors have a high level of the PARK2 gene, which may make them respond better to one of the treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between 18 and 75 years old.
- Your cancer must be advanced (stage III or IV) and a specific type (high-grade serous or endometrioid) of ovarian, primary peritoneal, or fallopian tube cancer.
- Your tumor must have a high level of a gene called PARK2, which the trial tests for.
- You must not have had any prior chemotherapy or other cancer treatments for this cancer.
- You need to be willing to provide tumor and blood samples for testing during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the targeted therapy RC48 and the chemotherapy drug carboplatin given before surgery for people with advanced ovarian cancer that has a specific protein (HER2). The goal is to see if this treatment can shrink the tumor enough to allow for complete removal during surgery.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this treatment shrinks the cancer more and makes surgery more effective.
This Phase 3 trial tests two chemotherapy regimens (TC vs BEP) for women with malignant sex cord-stromal tumors of the ovary. It aims to see which treatment works better after you’ve had initial surgery to diagnose and/or remove tumor.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.